Anavex Life Sciences Corp (AVXL)

[nidan7500]

ERett syndrome: Continued positive Real World Evidence (RWE) feedback from Rett syndrome patients and caregivers from the ongoing open-label extension trial and Compassionate Use Program for patients who participated in the Phase 2/3 EXCELLENCE trial encourages us to continue our partnership with the Rett syndrome community and to proceed with a Phase 3 12-week efficacy study. An educational presentation will be provided at the 2024 IRSF Rett Syndrome Scientific Meeting, taking place June 18 – June 19, 2024. ANAVEX®2-73 had previously received Fast Track designation, Rare Pediatric Disease designation and Orphan Drug designation from the FDA for the treatment of Rett syndrome.xcellent news-progress and RWE results commitment..

Great to see this "HARDBALL" kind of comments from Dr.M. .."Time to put our ,"BIG BOY PANTS ON."

https://www.anavex.com/post/anavex-life-sciences-reports-fiscal-2024-second-quarter-financial-results-and-provides-business?mc_cid=f5277b644b&mc_eid=a2160c00e9